<?phpxml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
>
<channel>
<title>The Meetingpoint at Slavyanski.net / tableparade3 / All</title>
<link>https://slavyanski.net/sb2020</link>
<description>Your Source for Social News and Networking</description>
<pubDate>Fri, 04 Sep 2020 11:33:47 +0000</pubDate>
<language>en</language>
<item>
	<title><![CDATA[Terase InhibitorC1 1205-01 (North American study) [36, 37]2/Randomized, doubleblind, placebocontrolledOpen-lab]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=terase-inhibitorc1-1205-01-north-american-study-36-372randomized-doubleblind-placebocontrolledopen-lab</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=terase-inhibitorc1-1205-01-north-american-study-36-372randomized-doubleblind-placebocontrolledopen-lab"><![CDATA[Terase InhibitorC1 1205-01 (North American study) [36, 37]2/Randomized, doubleblind, placebocontrolledOpen-lab]]></source>
	<description><![CDATA[Terase InhibitorC1 1205-01 (North American study) [36, 37]2/Randomized, doubleblind, placebocontrolledOpen-label extension39 patients (63  ) reported C1 AE Headache and nasopharyngitis most common AEs 10 patients (14  ) reported serious AEs, of whom 8 patients reported HAE attacks; 7 serious AEs reported in 4 patients included vertigo, pneumonia, urosepsis occurring twice and itching of the lips a ]]></description>
	<pubDate>Fri, 04 Sep 2020 11:33:47 +0000</pubDate>
	<author>tableparade3</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=terase-inhibitorc1-1205-01-north-american-study-36-372randomized-doubleblind-placebocontrolledopen-lab</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-7</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-7"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Thu, 03 Sep 2020 11:54:16 +0000</pubDate>
	<author>tableparade3</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-7</guid>
</item>

</channel>
</rss>
